Literature DB >> 19259667

Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines.

Javier G Casado1, Graham Pawelec, Sara Morgado, Beatriz Sanchez-Correa, Elena Delgado, Inmaculada Gayoso, Esther Duran, Rafael Solana, Raquel Tarazona.   

Abstract

Knowledge of the interactions between MHC-unrestricted cytotoxic effector cells and solid tumour cells is essential for introducing more effective NK cell-based immunotherapy protocols into clinical practise. Here, to begin to obtain an overview of the possible universe of molecules that could be involved in the interactions between immune effector cells and melanoma, we analyse the surface expression of adhesion and costimulatory molecules and of ligands for NK-activating receptors on a large panel of cell lines from the "European Searchable Tumour Cell Line and Data Bank" (ESTDAB, http://www.ebi.ac.uk/ipd/estdab/ ) and discuss their potential role in the immune response against this tumour. We show that most melanoma cell lines express not only adhesion molecules that are likely to favour their interaction with cells of the immune system, but also their interaction with endothelial cells potentially increasing their invasiveness and metastatic capacity. A high percentage of melanoma cell lines also express ligands for the NK-activating receptor NKG2D; whereas, the majority express MICA/B molecules, ULBP expression, however, was rarely found. In addition to these molecules, we also found that CD155 (poliovirus receptor, PVR) is expressed by the majority of melanoma cell lines, whereas CD112 (Nectin-2) expression was rare. These molecules are DNAM-1 ligands, a costimulatory molecule involved in NK cell-mediated cytotoxicity and cytokine production that also mediates costimulatory signals for triggering naïve T cell differentiation. The phenotypical characterisation of adhesion molecules and ligands for receptors involved in cell cytotoxicity on a large series of melanoma cell lines will contribute to the identification of markers useful for the development of new immunotherapy strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19259667     DOI: 10.1007/s00262-009-0682-y

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  48 in total

Review 1.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

2.  Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis.

Authors:  Olga DelaRosa; Beatriz Sánchez-Correa; Sara Morgado; Cristina Ramírez; Borja del Río; Ramón Menta; Eleuterio Lombardo; Raquel Tarazona; Javier G Casado
Journal:  Stem Cells Dev       Date:  2011-10-18       Impact factor: 3.272

Review 3.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 4.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

5.  Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.

Authors:  Vidyalakshmi Chandramohan; Jeffrey D Bryant; Hailan Piao; Stephen T Keir; Eric S Lipp; Michaela Lefaivre; Kathryn Perkinson; Darell D Bigner; Matthias Gromeier; Roger E McLendon
Journal:  Arch Pathol Lab Med       Date:  2017-08-22       Impact factor: 5.534

6.  T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Authors:  Sarah E Josefsson; Kanutte Huse; Arne Kolstad; Klaus Beiske; Daniela Pende; Chloé B Steen; Else Marit Inderberg; Ole Christian Lingjærde; Bjørn Østenstad; Erlend B Smeland; Ronald Levy; Jonathan M Irish; June H Myklebust
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

Review 7.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 8.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 9.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  KIR gene variability in cutaneous malignant melanoma: influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis.

Authors:  José A Campillo; Isabel Legaz; M Rocío López-Álvarez; José Miguel Bolarín; Beatriz Las Heras; Manuel Muro; Alfredo Minguela; María R Moya-Quiles; Rosa Blanco-García; Helios Martínez-Banaclocha; Ana M García-Alonso; M Rocío Alvarez-López; Jorge A Martínez-Escribano
Journal:  Immunogenetics       Date:  2013-01-31       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.